Targeted gene silencing of TLR4 using liposomal nanoparticles for preventing liver ischemia reperfusion injury
1Multi-Organ Transplant Program, London Health Sciences Centre, London, Canada.
Abstract:
RNAi-based therapy is a promising strategy for the prevention of ischemia-reperfusion injury (IRI). However, systemic administration of small interfering RNA (siRNA) may cause globally nonspecific targeting of all tissues, which impedes clinical use. Here we report a hepatocyte-specific delivery system for the treatment of liver IRI, using galactose-conjugated liposome nanoparticles (Gal-LipoNP). Heptocyte-specific targeting was validated by selective in vivo delivery as observed by increased Gal-LipoNP accumulation and gene silencing in the liver. Gal-LipoNP TLR4 siRNA treatment resulted in a significant decrease of serum alanine transferase (ALT) and aspartate transaminase (AST) in a hepatic IRI model. Histopathology displayed an overall reduction of the injury area in the Gal-LipoNP TLR4 siRNA treated mice. Additionally, neutrophil accumulation and lipid peroxidase-mediated tissue injury, detected by MPO, MDA and ROS respectively, were attenuated after Gal-LipoNP TLR4 siRNA treatment. Moreover, therapeutic effects of Gal-LipoNP TLR4 siRNA were associated with suppression of the inflammatory cytokines IL-1 and TNF-α. Taken together, this study is the first demonstration of liver IRI treatment using liver-specific siRNA delivery.
Insights
This study introduces a novel liver-specific delivery system for RNA interference therapy to treat liver ischemia-reperfusion injury (IRI). The galactose-conjugated liposome nanoparticles (Gal-LipoNP) effectively target liver cells, reducing injury and inflammation.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Hepatology
Background:
- Ischemia-reperfusion injury (IRI) poses a significant clinical challenge.
- Systemic small interfering RNA (siRNA) delivery for IRI lacks tissue specificity, limiting therapeutic efficacy.
- Targeted delivery of RNA interference therapeutics is crucial for effective treatment of liver IRI.
Purpose of the Study:
- To develop and validate a hepatocyte-specific delivery system for siRNA to treat liver IRI.
- To investigate the therapeutic potential of galactose-conjugated liposome nanoparticles (Gal-LipoNP) for liver IRI.
- To assess the efficacy of Gal-LipoNP carrying TLR4 siRNA in a murine model of liver IRI.
Main Methods:
- Development of galactose-conjugated liposome nanoparticles (Gal-LipoNP) for targeted delivery.
- In vivo validation of hepatocyte-specific targeting and gene silencing by Gal-LipoNP.
- Assessment of liver function markers (ALT, AST) and histopathology in a liver IRI model.
- Measurement of neutrophil infiltration (MPO), lipid peroxidation (MDA), reactive oxygen species (ROS), and inflammatory cytokines (IL-1, TNF-α).
Main Results:
- Gal-LipoNP demonstrated selective in vivo delivery and accumulation in hepatocytes.
- Treatment with Gal-LipoNP TLR4 siRNA significantly reduced serum ALT and AST levels.
- Histopathological analysis revealed a decreased injury area in treated mice.
- Neutrophil accumulation, MDA, ROS, IL-1, and TNF-α were significantly attenuated following Gal-LipoNP TLR4 siRNA treatment.
Conclusions:
- This study presents the first successful demonstration of liver-specific siRNA delivery for treating liver IRI.
- Gal-LipoNP serves as an effective platform for targeted delivery of therapeutic siRNA to hepatocytes.
- Hepatocyte-specific siRNA delivery holds significant promise for the clinical management of liver IRI.
